Phase I clinical trial of VSN16R, announced

[MSUK]

Phase I clinical trial of VSN16R, a potential treatment for spasticity in MS, announced

Canbex Therapeutics Ltd announced today that it has commenced a Phase I clinical trial to assess the safety and tolerability in humans of VSN16R, its novel, orally active lead compound aimed at treating spasticity in people with multiple sclerosis.

The first-in-man study of VSN16R will enrol a total of 72 healthy volunteers in a placebo-controlled, single ascending dose and multiple ascending dose design. The study is being carried out by Quintiles, the world’s leading clinical research organisation...... Read More - http://www.ms-uk.org/MSnews